These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 31308649

  • 1. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting.
    Steinmetz KO, Abenhardt B, Pabst S, Hänsel M, Kondla A, Bayer V, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
    [Abstract] [Full Text] [Related]

  • 2. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R.
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
    Derom E, Brusselle GG, Joos GF.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
    [Abstract] [Full Text] [Related]

  • 5. Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients.
    Valipour A, Tamm M, Kociánová J, Bayer V, Sanzharovskaya M, Medvedchikov A, Haaksma-Herczegh M, Mucsi J, Fridlender Z, Toma C, Belevskiy A, Matula B, Šorli J.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2343-2354. PubMed ID: 31632003
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, Fukuchi Y.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study.
    Kawachi S, Fujimoto K.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1167-1176. PubMed ID: 31213796
    [Abstract] [Full Text] [Related]

  • 8. Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.
    Muruganandan S, Jayaram L.
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1179-89. PubMed ID: 26124657
    [Abstract] [Full Text] [Related]

  • 9. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.
    Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
    [Abstract] [Full Text] [Related]

  • 10. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
    Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R.
    Ther Adv Respir Dis; 2018 Jun; 12():1753465818755091. PubMed ID: 29439648
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study.
    Valipour A, Avdeev S, Barczyk A, Bayer V, Fridlender Z, Georgieva M, Kudela O, Medvedchikov A, Miron R, Sanzharovskaya M, Šileikienė V, Šorli J, Spielmanns M, Szalai Z.
    Int J Chron Obstruct Pulmon Dis; 2021 Jun; 16():615-628. PubMed ID: 33731991
    [Abstract] [Full Text] [Related]

  • 12. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH, Kabbara WK, El Khoury GM, Al Assir SA.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun; 10():2347-56. PubMed ID: 26586940
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.
    Ichinose M, Minakata Y, Motegi T, Ueki J, Gon Y, Seki T, Anzai T, Nakamura S, Hirata K.
    Int J Chron Obstruct Pulmon Dis; 2018 Jun; 13():1407-1419. PubMed ID: 29750027
    [Abstract] [Full Text] [Related]

  • 14. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
    Buhl R, Magder S, Bothner U, Tetzlaff K, Voß F, Loaiza L, Vogelmeier CF, McGarvey L.
    Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
    [Abstract] [Full Text] [Related]

  • 15. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
    Calverley PMA, Anzueto AR, Carter K, Grönke L, Hallmann C, Jenkins C, Wedzicha J, Rabe KF.
    Lancet Respir Med; 2018 May; 6(5):337-344. PubMed ID: 29605624
    [Abstract] [Full Text] [Related]

  • 16. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
    Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N, Abrahams R, Schmidt O, Bjermer L.
    Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
    [Abstract] [Full Text] [Related]

  • 17. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct; 11():193-205. PubMed ID: 26893551
    [Abstract] [Full Text] [Related]

  • 18. A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol.
    Buhl R, Dreher M, Korn S, Taube C, Stock C, Zehendner CM, Kondla A, Vogelmeier CF.
    Int J Chron Obstruct Pulmon Dis; 2020 Oct; 15():2601-2608. PubMed ID: 33122898
    [Abstract] [Full Text] [Related]

  • 19. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
    Kardos P, Hagedorn-Peinz I.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct; 13():69-77. PubMed ID: 29317812
    [Abstract] [Full Text] [Related]

  • 20. Assessment of physical functioning in patients with chronic obstructive pulmonary disease (COPD) requiring long-acting dual bronchodilation in routine clinical practice.
    Molina París J, Alonso Hernández PM, Díez García JA, Gonzalez Uribe-Etxebarria I, Yelo García J, Galera Llorca J, Aguilar H, Ribera X, OTIVACTO Spanish investigator's group.
    Semergen; 2021 Oct; 47(5):295-304. PubMed ID: 33359383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.